$2.24 Billion is the total value of NEA Management Company, LLC's 31 reported holdings in Q2 2013. The portfolio turnover from Q1 2013 to Q2 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GRPN | New | GROUPON INC | $747,724,000 | – | 87,453,072 | +100.0% | 33.40% | – |
| TSRO | New | TESARO INC | $322,628,000 | – | 9,854,255 | +100.0% | 14.41% | – |
| EPZM | New | EPIZYME INC | $169,894,000 | – | 6,039,589 | +100.0% | 7.59% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $152,700,000 | – | 2,279,781 | +100.0% | 6.82% | – |
| XOOM | New | XOOM CORP | $115,813,000 | – | 5,052,935 | +100.0% | 5.17% | – |
| FIO | New | FUSION-IO INC | $100,227,000 | – | 7,038,379 | +100.0% | 4.48% | – |
| OMTH | New | OMTHERA PHARMACEUTICA-LS INC | $77,650,000 | – | 5,838,333 | +100.0% | 3.47% | – |
| MM | New | MILLENNIAL MEDIA INC | $71,638,000 | – | 8,224,752 | +100.0% | 3.20% | – |
| SUPN | New | SUPERNUS PHARMACEUTI-CALS INC | $68,480,000 | – | 10,650,000 | +100.0% | 3.06% | – |
| HPTX | New | HYPERION THERAPEUTICS INC | $63,453,000 | – | 2,884,221 | +100.0% | 2.83% | – |
| ECOM | New | CHANNELADVISOR CORP | $43,536,000 | – | 2,767,697 | +100.0% | 1.94% | – |
| WIFI | New | BOINGO WIRELESS INC | $40,000,000 | – | 6,441,293 | +100.0% | 1.79% | – |
| ADNC | New | AUDIENCE INC | $38,018,000 | – | 2,878,005 | +100.0% | 1.70% | – |
| SNSS | New | SUNESIS PHARMACEUTI-CALS INC | $29,254,000 | – | 5,636,573 | +100.0% | 1.31% | – |
| LXRX | New | LEXICON PHARMACEUTI-CALS INC | $25,337,000 | – | 11,676,000 | +100.0% | 1.13% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $21,086,000 | – | 1,825,600 | +100.0% | 0.94% | – |
| TRGT | New | TARGACEPT INC | $19,527,000 | – | 4,572,999 | +100.0% | 0.87% | – |
| CADX | New | CADENCE PHARMACEUTI-CALS INC | $14,119,000 | – | 2,070,286 | +100.0% | 0.63% | – |
| LNKD | New | LINKEDIN CORP | $13,634,000 | – | 76,467 | +100.0% | 0.61% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $13,172,000 | – | 5,653,029 | +100.0% | 0.59% | – |
| GLUU | New | GLU MOBILE INC | $13,136,000 | – | 5,943,793 | +100.0% | 0.59% | – |
| ALIM | New | ALIMERA SCIENCES INC | $13,085,000 | – | 2,681,250 | +100.0% | 0.58% | – |
| ITMN | New | INTERMUNE INC | $12,900,000 | – | 1,341,000 | +100.0% | 0.58% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $10,832,000 | – | 3,243,150 | +100.0% | 0.48% | – |
| EXEL | New | EXELIXIS INC | $10,020,000 | – | 2,207,000 | +100.0% | 0.45% | – |
| SMICY | New | SEMICONDUCTOR MFG INTL CORPsponsored adr | $8,304,000 | – | 2,275,177 | +100.0% | 0.37% | – |
| SLTM | New | SOLTA MED INC | $6,520,000 | – | 2,859,577 | +100.0% | 0.29% | – |
| TSPT | New | TRANSCEPT PHARMACEUTI-CALS INC | $6,302,000 | – | 2,086,755 | +100.0% | 0.28% | – |
| ARQL | New | ARQULE INC | $5,847,000 | – | 2,520,316 | +100.0% | 0.26% | – |
| ZHNE | New | ZHONE TECHNOLOGIES INC | $3,825,000 | – | 4,781,290 | +100.0% | 0.17% | – |
| NURO | New | NEUROMETRIX INC | $115,000 | – | 57,273 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-07-26
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.